問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
周聖傑
下載
2021-12-01 - 2025-12-31
Condition/Disease
Test Drug
Participate Sites5Sites
Not yet recruiting3Sites
Recruiting2Sites
2017-12-01 - 2027-11-24
Participate Sites3Sites
Recruiting3Sites
2023-10-01 - 2028-10-07
Participate Sites1Sites
Recruiting1Sites
2020-12-21 - 2023-12-31
relapsed or refractory multiple myeloma
SAR442085
Participate Sites2Sites
2023-03-01 - 2026-12-31
2022-02-01 - 2026-12-31
Recruiting5Sites
2022-11-15 - 2028-11-26
2019-09-01 - 2027-12-31
The study compared the differences between the trial drug before and after infusion, and evaluated the non-inferiority of the annual average bleeding rate (ABR) of total bleeding events (treatment-free and treatment-free) from week 12 to month 15 compared with standard of care (SOC) FIX prophylactic alternative therapy.
injection
2022-09-01 - 2028-12-31
xxxxxx
Participate Sites4Sites
Recruiting4Sites
2022-04-01 - 2029-10-31
全部
